Cost-minimization analysis of individually tailored or fixed-scheduled rituximab maintenance therapy for antineutrophil-cytoplasm antibody associated vasculitides
Objective: Patients included in MAINRITSAN2 trial received either an individually tailored or a fixed-schedule therapy with rituximab as maintenance treatment of antineutrophil cytoplasm antibody associated vasculitides. The aim of this study was to compare the real-world costs of both arms. Method:...
Saved in:
Main Authors: | Ana Belén Guisado-Gil (Author), Marina Muñoz-Burgos (Author), Ana Ortega-Eslava (Author), Francisco Javier García-Hernández (Author), Bernardo Santos-Ramos (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2020-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives
by: Moog P, et al.
Published: (2015) -
Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
by: Zhi-Ying Li, et al.
Published: (2020) -
Antineutrophil cytoplasmic antibodies
by: G.D. Sebastiani
Published: (2011) -
Health-related quality of life after Rituximab treatment of patients with antineutrophil cytoplasmic antibody-associated vasculitis
by: Iva Parvova, et al.
Published: (2024) -
Proteinase 3 (PR3)-Antineutrophil Cytoplasmic Antibody in a Patient with Minimal Change Disease: An Unusual Finding
by: Joana Freitas, et al.
Published: (2022)